Stockscreener 앱 받기
19.20
6.25%
1.13
시간 외 거래:
19.20
전일 마감가:
$18.07
열려 있는:
$18.33
하루 거래량:
3.45M
Relative Volume:
1.95
시가총액:
$3.17B
수익:
-
순이익/손실:
$-451.71M
주가수익비율:
-5.9515
EPS:
-3.2261
순현금흐름:
$-462.19M
1주 성능:
+8.66%
1개월 성능:
+11.05%
6개월 성능:
+1.59%
1년 성능:
+76.80%
1일 변동 폭
$18.24
$20.44
1주일 범위
$17.40
$20.44
52주 변동 폭
$8.06
$25.00
다인 테라 Stock (DYN) Company Profile
명칭
Dyne Therapeutics Inc
전화
(781) 786-8230
주소
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
19.20 | 3.10B | 0 | -451.71M | -462.19M | -3.2261 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
다인 테라 Stock (DYN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-10-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-25 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | 개시 | Bernstein | Mkt Perform |
| 2025-06-11 | 재개 | Raymond James | Outperform |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-29 | 개시 | Evercore ISI | Outperform |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-13 | 개시 | Robert W. Baird | Outperform |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-10-24 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-05-21 | 재확인 | Chardan Capital Markets | Buy |
| 2024-04-30 | 개시 | Morgan Stanley | Overweight |
| 2024-02-20 | 개시 | H.C. Wainwright | Buy |
| 2023-02-27 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 개시 | Oppenheimer | Outperform |
| 2023-01-26 | 개시 | Guggenheim | Buy |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Outperform |
| 2020-10-12 | 개시 | JP Morgan | Overweight |
| 2020-10-12 | 개시 | Jefferies | Buy |
| 2020-10-12 | 개시 | Piper Sandler | Overweight |
| 2020-10-12 | 개시 | Stifel | Buy |
모두보기
다인 테라 주식(DYN)의 최신 뉴스
Trading Systems Reacting to (DYN) Volatility - Stock Traders Daily
Dyne Therapeutics (DYN) Concludes Phase 1/2 ACHIEVE Trial Enrollment - Insider Monkey
Clearbridge Investments LLC Makes New Investment in Dyne Therapeutics, Inc. $DYN - MarketBeat
Cibc World Market Inc. Takes Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne therapeutics director Brian Posner buys $33,880 in stock By Investing.com - Investing.com Canada
Dyne therapeutics director Brian Posner buys $33,880 in stock - Investing.com
Insider Buying: Brian Posner Acquires Additional Shares of Dyne Therapeutics Inc (DYN) - GuruFocus
Director at Dyne Therapeutics (DYN) receives 35,152 stock options - Stock Titan
Director Lubner gets 35,152 Dyne (DYN) options at $17.04 strike - Stock Titan
Dyne Therapeutics director granted 35,152 options | DYN Insider Trading - Stock Titan
Director at Dyne Therapeutics (NASDAQ: DYN) granted 35,152 stock options at $17.04 - Stock Titan
Director at Dyne Therapeutics (DYN) receives grant of 35,152 stock options - Stock Titan
Dyne Therapeutics (DYN) director buys stock and receives 35,152-share option grant - Stock Titan
Dyne Therapeutics (DYN) investors double share authorization and approve all proposals - Stock Titan
Dyne spikes as late-stage trial for Duchenne therapy gets underway - MSN
Dyne Therapeutics (DYN) director Brian Posner buys 2,500 shares in open market - Stock Titan
Dyne Therapeutics (DYN) Reaches Key Regulatory Milestone - Insider Monkey
A Look At Dyne Therapeutics (DYN) Valuation After Key ACHIEVE Trial Enrollment Milestone - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Evercore Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $33 - Moomoo
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $47 - Moomoo
Dyne Therapeutics (DYN) Completes Enrollment in Phase 1/2 ACHIEVE Trial - GuruFocus
How Dyne Therapeutics Inc. (DYN) Affects Rotational Strategy Timing - Stock Traders Daily
Dyne Therapeutics stock hits 52-week low at 17.54 USD By Investing.com - Investing.com Australia
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 - Investing News Network
DYN: BLA filed for DMD, DM1 trial fully enrolled, and robust pipeline advances with strong financials - TradingView
Dyne completes enrollment in DM1 therapy trial expansion cohort By Investing.com - Investing.com Australia
Dyne Fully Enrolls ACHIEVE Trial for DM1 Therapy - TipRanks
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1) - The Manila Times
Dyne completes enrollment of 71-patient ACHIEVE registrational cohort; topline data due Q1 2027 - TradingView
Dyne Therapeutics (Nasdaq: DYN) hits key ACHIEVE trial enrollment milestone - Stock Titan
Experimental DM1 drug hits key trial milestone, Dyne eyes 2028 US launch - Stock Titan
Dyne Therapeutics stock hits 52-week low at 17.54 USD - Investing.com
DYN stock gains as it gears up for accelerated approval of DMD therapy: Wall Street sees 140% upside - MSN
Dyne Therapeutics stock gains 4.5% after BLA filing for DMD therapy - MSN
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean - The Motley Fool
Dyne Therapeutics (DYN) Is Up 11.3% After FDA BLA Filing For DMD Drug Candidate Zeleciment Rostudirsen - Sahm
Dyne therapeutics director Brian Posner buys $36,420 in stock By Investing.com - Investing.com Australia
Dyne therapeutics director Brian Posner buys $36,420 in stock - Investing.com
Dyne Therapeutics (DYN) director Brian Posner buys 2,000 shares in open market - Stock Titan
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy - Yahoo Finance
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Raises Target Price to $47 - Moomoo
Dyne Therapeutics (DYN) Surges 5.87% as Biotech Momentum BuildsLow Volatility Picks - The Legal Advocate
다인 테라 (DYN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
다인 테라 주식 (DYN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Posner Brian S | Director |
Jun 08 '26 |
Buy |
16.94 |
2,000 |
33,880 |
24,500 |
| Posner Brian S | Director |
Jun 03 '26 |
Buy |
17.48 |
2,500 |
43,700 |
22,500 |
| Posner Brian S | Director |
May 26 '26 |
Buy |
18.21 |
2,000 |
36,420 |
20,000 |
| Posner Brian S | Director |
May 20 '26 |
Buy |
17.12 |
2,500 |
42,800 |
18,000 |
| Friedl-Naderer Johanna | Chief Commercial Officer |
May 13 '26 |
Sale |
18.36 |
228 |
4,186 |
154,353 |
| Kerr Douglas | Chief Medical Officer |
May 13 '26 |
Sale |
18.36 |
1,564 |
28,715 |
170,042 |
| Lucera Erick | Chief Financial Officer |
May 13 '26 |
Sale |
18.36 |
1,448 |
26,585 |
123,925 |
| Cox John | CEO & President |
May 13 '26 |
Sale |
18.36 |
3,311 |
60,790 |
370,834 |
2.60%
0.94%
자본화:
|
볼륨(24시간):